Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2000; 83(05): 637-638
DOI: 10.1055/s-0037-1613882
DOI: 10.1055/s-0037-1613882
Commentary
Recombinant Factor VIIa Is a Pan-hemostatic Agent?
This study was supported in part by Health Services Administration Grant MCB-360001; Health and Human Services Grant HS-30567; the Regional Comprehensive Hemophilia Diagnostic and Treatment Center; the Margie Boas Fund; the International Hemophilia Training Center of the World Federation of Hemophilia; the Polly Annenberg Levee Hematology Center, Department of Medicine, Mount Sinai School of Medicine of the City University of New York; and grant 5MO1RR0071 for the Mount Sinai General Clinical Research Center from the National Center for Research Resources, National Institutes of Health.
Further Information
Publication History
Publication Date:
08 December 2017 (online)
-
References
- 1 Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82: 531-4.
- 2 Monroe DM, Hoffman M, Oliver JA, Robert HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
- 3 Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
- 4 Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-6.
- 5 Hedner U. Recombinant activated factor VII as a universal hemostatic agent. Blood Coag Fibrinol 1998; (Suppl. 01) 147-52.
- 6 d’Oiron R, Ménart C, Trzeciak MC, Nurden P, Fressinaud E, Dreyfus M, Laurian Y, Négrier C. Recombinant factor VIIa in Glanzmann’s thrombasthenia: A potential therapeutic place. Thromb Haemost 2000; 83: 644-7.
- 7 Turacek PL, Richter G, Muchitson EM, Pichler L, Schwarz HP, Morrissey J. Thrombogenicity of recombinant factor VIIa and recombinant soluble tissue factor in an in vivo rabbit model. Thromb Haemost 1997; Suppl. June: 222: 903.
- 8 Clinical experience with NovoSeven. Summary of efficacy and safety. August 1996.
- 9 European public assessment report on NovoSeven. 1996; 28: 10.
- 10 Peerlinck KK, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775-6.